The sector, which reached a market valuation of USD 3.2 billion across seven major markets in 2025, is primarily propelled by the United States, which currently commands a 59% share of total expenditure. Growth is further sustained by an increasing incidence of relapsed and refractory lymphoma subtypes, including diffuse large B-cell lymphoma and mantle cell lymphoma, where patient options have historically been limited.

Innovation remains a central driver, with a robust pipeline of investigational therapies—such as Zamtocabtagene autoleucel, Rapcabtagene autoleucel, and WU-CART-007—entering clinical evaluation. These next-generation candidates, alongside established products like Tecartus and Breyanzi, are set to intensify competition. Developers are now prioritizing allogeneic platforms and dual-targeting approaches, such as the CD19/CD20-focused LB2501, to improve both safety profiles and accessibility for patients who have failed multiple prior lines of therapy.